Pharmafile Logo

News and Press Releases

Pharma and Regulatory Giants Tackle AI Trust and Legislative Challenges at Largest Ever Pistoia Alliance Annual Conference

Survey of life sciences experts found 70% recognise potential for AI, but many are struggling to get started or implement it at scale due to challenges including data integrity and...

Category: Clinical Trials, Logistics
Posted: May 8, 2024

The Pistoia Alliance
info@pistoiaalliance.org
401 Edgewater Pl, Wakefield, Massachusetts, US

How the Birmingham Drug Discovery Hub created an investment-ready ‘drug library’

18 April 2024 -- Birmingham, UK -- A novel approach to drug discovery is enabling University of Birmingham, UK, researchers to overcome the ‘valley of death’, where projects fail due...

Category: Drug Discovery
Posted: April 18, 2024

The University of Birmingham
Edgbaston Birmingham, B15 2TT

GSK’s Jemperli▼ (dostarlimab) is accepted for use within NHS Scotland, in line with its licence, in eligible endometrial cancer patients in first line setting

Clinicians in Scotland will now be able to use dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced...

Category: Pharmaceutical
Posted: April 8, 2024

X‑Chem Adds Chief Technology Officer to Bolster Its Digital Drug Discovery Strategy 

2 April 2024 -- Massachusetts, US -- X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the addition of Dr Erin Davis as chief technology officer....

Category: Drug Discovery
Posted: April 2, 2024

X-Chem
info@x-chemrx.com
100 Beaver Street Waltham, MA 02453

Semarion introduces SemaCyte Multiplexing Platform to enhance cell assay data quality and speed during drug discovery

Expansion to SemaCyte Microcarrier platform enables optical barcoding and pooling of adherent cells to augment drug discovery high-content imaging and other screening processes Access available through Semarion’s Early Adopter Programme....

Category: Drug Discovery
Posted: March 20, 2024

Semarion
info@semarion.com
Cavendish Laboratories JJ Thomson Ave Cambridge CB3 0HE UK

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics 11 March 2024 -- Dundee, UK --...

Category: Drug Discovery
Posted: March 11, 2024

Ubiquigent
services@ubiquigent.com
University Incubator Dundee Technopole James Lindsay Place Dundee DD1 5JJ Scotland, UK

Jemperli (dostarlimab) becomes the first immunotherapy treatment to receive NICE recommendation for use, in line with its license, in eligible endometrial cancer patients in first line setting

This final draft guidance recommends the use of dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or...

Category: Clinical Trials, Drug Discovery
Posted: March 5, 2024

GSK
980 Great West Rd, London TW8 9GS

Real-World Evidence Demonstrates Feasibility and Safety of Outpatient Administration of Yescarta (axicabtagene ciloleucel)

Findings show comparable safety for patients administered axicabtagene ciloleucel in the outpatient setting in the US to inpatient infusion  Real-world evidence supports further exploration of use of outpatient administration of...

Category: Clinical Trials
Posted: February 15, 2024

Kite Pharma
2400 Broadway Santa Monica, CA 90404

NICE has issued guidance for GSK’s Omjjara (momelotinib) as a treatment option for disease-related splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia

Myelofibrosis is a rare blood cancer that can result in the progressive scarring of bone marrow (fibrosis), impairing its normal function There are approximately 1,970 people living with myelofibrosis across...

Category: Clinical Trials
Posted: February 15, 2024

GSK
980 Great West Rd, London TW8 9GS

Aston University and University of Warwick team wins £1.8m for research to aid drug discovery and sustainable chemical production

The team will engineer cells to make membrane proteins efficiently The proteins will be used for drug discovery and screening, and as catalysts in sustainable chemical production The £1.8m Engineering...

Category: Drug Discovery
Posted: February 12, 2024

Aston University
Aston University Birmingham B4 7ET UK

Medicines and Healthcare Products Regulatory Agencyauthorises GSK’s Omjjara (momelotinib) in Great Britainfor treating splenomegaly or symptoms in adultmyelofibrosis patients with moderate to severe anaemia

First JAK inhibitor treatment in Great Britain specifically indicated for both newly diagnosed and previously treated myelofibrosis patients with moderate to severe anaemia 31 January 2024 -- Middlesex, UK --...

Category: Pharmaceutical
Posted: January 31, 2024

GSK
980 Great West Rd, London TW8 9GS